- Molecular NamePentostatin
- Synonym2'-DCF; 2'-Deoxycoformycin; 2'-Dexoycoformycin; Deoxycoformycin; pentostatin
- Weight268.273
- Drugbank_IDDB00552
- ACS_NO53910-25-1
- Show 3D model
- LogP (experiment)-2.09
- LogP (predicted, AB/LogP v2.0)-2.05
- pka5.2
- LogD (pH=7, predicted)-2.2
- Solubility (experiment)30 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-1.05
- LogSw (predicted, AB/LogsW2.0)14125.9
- Sw (mg/ml) (predicted, ACD/Labs)11.66
- No.of HBond Donors4
- No.of HBond Acceptors8
- No.of Rotatable Bonds2
- TPSA112.13
- StatusFDA approved
- AdministrationIntravenous
- PharmacologyAn anticancer chemotherapeutic drug.
- Absorption_valueN/A
- Absorption (description)Not absorbed orally, crosses blood brain barrier.
- Caco_2N/A
- BioavailabilityN/A
- Protein binding4.0
- Volume of distribution (VD)42.4 L (terminal phase); 36.9 L (steady state)
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic, minor
- Half lifemean 5.7 h, (3~15 h, measured with sampling for 24 h); may be increased in patients with impaired renal function.
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicitySide effects include lethargy, rash, fatigue, nausea and myelosuppression.
- LD50 (rat)N/A
- LD50 (mouse)LD50=128 mg/kg